Low dose dobutamine echocardiography for predicting functional recovery after coronary revascularisation.

Division of Cardiology, Federico II University, Via Sergio Pansini 5, I-80131 Naples, Italy.
Heart (British Cardiac Society) (Impact Factor: 6.02). 12/2001; 86(6):679-86.
Source: PubMed

ABSTRACT To evaluate the effects of chronic coronary occlusion on the accuracy of low dose dobutamine echocardiography in predicting recovery of dysfunctional myocardium after revascularisation.
Retrospective study.
Tertiary referral centre.
53 consecutive patients with >/= 70% stenosis of the left anterior descending coronary artery (LAD) and regional ventricular dysfunction (group 1, non-occluded LAD; group 2, occluded LAD) who underwent dobutamine echocardiography.
26 patients underwent coronary artery bypass grafting and 27 had percutaneous transluminal coronary angioplasty.
Baseline studies before revascularisation included cross sectional echocardiography at rest and during dobutamine infusion (5-10 microgram), and coronary angiography. The dobutamine study was performed mean (SD) 35 (28) days before revascularisation. Echocardiography at rest was repeated 90 (48) days after revascularisation.
Of 296 dysfunctional segments, 63 in group 1 (43%; 63/146) and 69 in group 2 (46%; 69/150) (NS) improved at follow up. Mean (SD) regional wall motion score index decreased from 1.97 (0.48) (95% confidence interval (CI) 1.01 to 2.93) before revascularisation to 1.74 (0.52) (95% CI 0.70 to 2.78) at follow up in group 1 (p = 0.001), and from 2.12 (0.41) (95% CI 1.30 to 2.98) to 1.88 (0.36) (95% CI 1.16 to 2.60) in group 2 (p = 0.0006). In group 1, sensitivity (87% v 52%; p < 0.0001), negative predictive value (88% v 65%; p = 0.001), and accuracy (77% v 64%; p = 0.01) were all significantly higher than in group 2, despite the angiographic evidence of collaterals in patients with occluded vessels.
Dobutamine echocardiography shows reduced sensitivity in predicting recovery of dysfunctional myocardium supplied by totally occluded vessels. Thus caution should be used in selecting such patients for revascularisation on the basis of a viability assessment made in this way.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of myocardial viability by cardiac imaging plays a critical role in the decision-making therapeutic strategies for patients with ischaemic left ventricular (LV) dysfunction. Application of cardiac imaging for viability assessment follows distinct pathophysiological approaches, namely regional assessment of perfusion by either single-photon emission computed tomography (SPECT) or positron emission tomography (PET), regional assessment of perfusion and metabolism by PET, verification of residual contractile reserve in dysfunctional myocardium using dobutamine stimulation, or direct visualization of necrotic myocardium by magnetic resonance imaging (MRI) or multi-detector computed tomography (MDCT). Identification of viability bears relevant implications because it has been repeatedly reported that in patients with viability remaining in medical therapy, mortality is substantially higher than in those with viability undergoing revascularization.
    12/2008: pages 341-356;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The assessment of myocardial viability may be an important component of the evaluation of patients with coronary artery disease and left ventricular dysfunction. The primary goal of viability assessment in such patients is to guide therapeutic decisions by determining which patients would most likely benefit from revascularization. In patients with chronic coronary artery disease, left ventricular dysfunction may be a consequence of prior myocardium infarction, which is an irreversible condition, or reversible ischemic states such as stunning and hibernation. Imaging techniques utilize several methods to assess myocardial viability: left ventricular function, morphology, perfusion, and metabolism. Each technique (echocardiography, nuclear imaging, magnetic resonance imaging, and x-ray computed tomography) has the ability to assess one or more of these parameters. This article describes how each of these imaging modalities can be used to assess myocardial viability, and reviews the relative strengths and limitations of each technique.
    Current Cardiology Reports 04/2012; 14(2):234-43.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular dysfunction in the setting of severe coronary artery disease poses a major diagnostic and therapeutic dilemma. While this clinical scenario is generally associated with poor outcomes, some but not all patients benefit from coronary revascularization. For example, patients with severe, transmural myocardial infarctions may derive little or no functional benefit from revascularization, as the underlying myocardium is irreversibly scarred. Furthermore, these patients may be exposed to high procedural risks with a low likelihood of deriving any perceivable benefit. Conversely, hibernating myocardium reflects a substrate whereby the nonfunctioning myocytes are chronically ischemic but may be viable. Existing data are somewhat inconclusive with regard to the benefits of performing viability testing in patients with ischemic cardiomyopathy. While this testing may predict regional and global functional myocardial recovery, the ability of viability studies to predict survival and prognosis remains unproven in prospective studies to date. Yet, viability testing may still be a valuable tool to guide therapeutic options in selected patients. A variety of noninvasive viability tests are available and newer technologies, such as PET and cardiac MRI, are likely to advance the scientific field in years to come.
    Future Cardiology 11/2012; 8(6):819-36.

Full-text (2 Sources)

Available from
Jun 2, 2014